Advancement of targeted protein degradation strategies as therapeutics for undruggable disease targets

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. Nisar S, Masoodi T, Prabhu KS et al. Natural products as chemo-radiation therapy sensitizers in cancers. Biomed. Pharmacother. 154, DOI:10.1016/j.biopha.2022.113610 (2022).
  Google Scholar
• 2. Puzari U, Fernandes PA, Mukherjee AK. Advances in the therapeutic application of small-molecule inhibitors and repurposed drugs against snakebite. J. Med. Chem. 64(19), 13938–13979 (2021).
  Medline CASGoogle Scholar
• 3. Zhang H, Saravanan KM, Lin J et al. DeepBindPoc: a deep learning method to rank ligand binding pockets using molecular vector representation. PeerJ 8, e8864 (2020).
  MedlineGoogle Scholar
• 4. Saravanan KM, Kannan M, Meera P, Bharathkumar N, Anand T. E3 ligases: a potential multi-drug target for different types of cancers and neurological disorders. Future Med. Chem. 14(3), 187–201 (2022).
  CASGoogle Scholar
• 5. Sánchez-Ramón S, Conejero L, Netea MG, Sancho D, Palomares Ó, Subiza JL. Trained Immunity-based vaccines: a new paradigm for the development of broad-spectrum anti-infectious formulations. Front. Immunol. 9, 2936 (2018).
  Medline CASGoogle Scholar
• 6. Mannes M, Martin C, Menet C, Ballet S. Wandering beyond small molecules: peptides as allosteric protein modulators. Trends Pharmacol. Sci. 43(5), 406–423 (2022).
  Medline CASGoogle Scholar
• 7. Chamberlain PP, Hamann LG. Development of targeted protein degradation therapeutics. Nat. Chem. Biol. 15(10), 937–944 (2019). •• Describes the discoveries that laid the foundation for future degradation therapeutics, focusing on those classes of small molecules that redirect E3 ubiquitin ligases to non-native substrates.
  Medline CASGoogle Scholar
• 8. Kumar D, Mishra A, Lisok A et al. Pharmacodynamic measures within tumors expose differential activity of PD(L)-1 antibody therapeutics. Proc. Natl Acad. Sci. USA 118(37), e2107982118 (2021).
  Medline CASGoogle Scholar
• 9. Makurvet FD. Biologics vs. small molecules: drug costs and patient access. Med. Drug Discov. 9, DOI:10.1016/j.medidd.2020.100075 (2021).
  Google Scholar
• 10. Wang Z, Yang B. Strategies of polypharmacology. In: Polypharmacology: Principles and Methodologies. Springer International Publishing, Cham, Switzerland, 43–72 (2022).
  Google Scholar
• 11. Liu Y, Wang X, Wang G, Yang Y, Yuan Y, Ouyang L. The past, present and future of potential small-molecule drugs targeting p53-MDM2/MDMX for cancer therapy. Eur. J. Med. Chem. 176, 92–104 (2019).
  Medline CASGoogle Scholar
• 12. Röth S, Fulcher LJ, Sapkota GP. Advances in targeted degradation of endogenous proteins. Cell. Mol. Life Sci. 76(14), 2761–2777 (2019). • Appraisal of the different targeted proteolytic systems and discussion of their applications in understanding protein function, as well as their potential in therapeutics.
  Medline CASGoogle Scholar
• 13. Kundu A, Chen C, Mudumba S. Therapeutic modality aspects in safety and efficacy of ocular drugs. In: Handbook of Basic and Clinical Ocular Pharmacology and Therapeutics. Ohia SESharif NA (Eds). Academic Press, MA, USA, 119–129 (2022).
  Google Scholar
• 14. Saravanan KM, Selvaraj S. Dihedral angle preferences of amino acid residues forming various non-local interactions in proteins. J. Biol. Phys. 43(2), 265–278 (2017).
  Medline CASGoogle Scholar
• 15. Zu M, Ma Y, Cannup B et al. Oral delivery of natural active small molecules by polymeric nanoparticles for the treatment of inflammatory bowel diseases. Adv. Drug Deliv. Rev. 176, DOI:10.1016/j.addr.2021.113887 (2021).
  MedlineGoogle Scholar
• 16. Thirunavukarasou A, Govindarajalu G, Singh P, Bandi V, Muthu K, Baluchamy S. Cullin 4A and 4B ubiquitin ligases interact with γ-tubulin and induce its polyubiquitination. Mol. Cell. Biochem. 401(1–2), 219–228 (2015).
  Medline CASGoogle Scholar
• 17. Thirunavukarasou A, Singh P, Govindarajalu G, Bandi V, Baluchamy S. E3 ubiquitin ligase cullin4B mediated polyubiquitination of p53 for its degradation. Mol. Cell. Biochem. 390(1), 93–100 (2014).
  Medline CASGoogle Scholar
• 18. Ji CH, Lee MJ, Kim HY et al. Targeted protein degradation via the autophagy-lysosome system: AUTOTAC (AUTOphagy-TArgeting Chimera). Autophagy 18(9), 2259–2262 (2022). •• Suggests that AUTOTAC provides a platform for selective proteolysis as a research tool and in drug development.
  Medline CASGoogle Scholar
• 19. Glickman MH, Ciechanover A. The ubiquitin–proteasome proteolytic pathway: destruction for the sake of construction. Physiol. Rev. 82(2), 373–428 (2002).
  Medline CASGoogle Scholar
• 20. Hershko A, Ciechanover A, Varshavsky A. The ubiquitin system. Nat. Med. 6(10), 1073–1081 (2000).
  Medline CASGoogle Scholar
• 21. Fang Y, Wang J, Zhao M et al. Progress and challenges in targeted protein degradation for neurodegenerative disease therapy. J. Med. Chem. 65(17), 11454–11477 (2022). •• Reviews the latest targeted protein degradation (TPD) technologies, introduces their targets and technical characteristics and discusses the emerging TPD technologies with potential in neural disorder research.
  Medline CASGoogle Scholar
• 22. Frankowska N, Lisowska K, Witkowski JM. Proteolysis dysfunction in the process of aging and age-related diseases. Front. Aging 3, DOI:10.3389/fragi.2022.927630 (2022).
  MedlineGoogle Scholar
• 23. Wolska-Washer A, Smolewski P. Targeting protein degradation pathways in tumors: focusing on their role in hematological malignancies. Cancers (Basel) 14(15), 3778 (2022).
  Medline CASGoogle Scholar
• 24. Hwang HJ, Park Y, Kim YK. UPF1: from mRNA surveillance to protein quality control. Biomedicines 9(8), 995 (2021).
  Medline CASGoogle Scholar
• 25. Liu W, Tang X, Qi X et al. The ubiquitin conjugating enzyme: an important ubiquitin transfer platform in ubiquitin–proteasome system. Int. J. Mol. Sci. 21(8), 2894 (2020).
  Medline CASGoogle Scholar
• 26. Ikeda F. Ubiquitin conjugating enzymes in the regulation of the autophagy-dependent degradation pathway. Matrix Biol. 100–101, 23–29 (2021).
  Medline CASGoogle Scholar
• 27. Mehrtash AB, Hochstrasser M. Ubiquitin-dependent protein degradation at the endoplasmic reticulum and nuclear envelope. Semin. Cell Dev. Biol. 93, 111–124 (2019).
  Medline CASGoogle Scholar
• 28. Tsuchiya H, Endo A, Saeki Y. Multi-step ubiquitin decoding mechanism for proteasomal degradation. Pharmaceuticals 13(6), 128 (2020).
  Medline CASGoogle Scholar
• 29. Deng L, Meng T, Chen L, Wei W, Wang P. The role of ubiquitination in tumorigenesis and targeted drug discovery. Signal Transduct. Target. Ther. 5(1), 11 (2020).
  Medline CASGoogle Scholar
• 30. Soini L, Leysen S, Davis J, Ottmann C. Molecular glues to stabilize protein–protein interactions. Curr. Opin. Chem. Biol. 69, DOI:10.1016/j.cbpa.2022.102169 (2022).
  MedlineGoogle Scholar
• 31. Hanzl A, Winter GE. Targeted protein degradation: current and future challenges. Curr. Opin. Chem. Biol. 56, 35–41 (2020).
  Medline CASGoogle Scholar
• 32. Lai AC, Crews CM. Induced protein degradation: an emerging drug discovery paradigm. Nat. Rev. Drug Discov. 16(2), 101–114 (2017).
  Medline CASGoogle Scholar
• 33. Yamamoto J, Ito T, Yamaguchi Y, Handa H. Discovery of CRBN as a target of thalidomide: a breakthrough for progress in the development of protein degraders. Chem. Soc. Rev. 51(15), 6234–6250 (2022).
  Medline CASGoogle Scholar
• 34. Li H, Dong J, Cai M, Xu Z, Cheng X-D, Qin J-J. Protein degradation technology: a strategic paradigm shift in drug discovery. J. Hematol. Oncol. 14(1), 138 (2021).
  Medline CASGoogle Scholar
• 35. Hines J, Lartigue S, Dong H, Qian Y, Crews CM. MDM2-recruiting PROTAC offers superior, synergistic antiproliferative activity via simultaneous degradation of BRD4 and stabilization of p53. Cancer Res. 79(1), 251–262 (2019).
  Medline CASGoogle Scholar
• 36. Troup RI, Fallan C, Baud MGJ. Current strategies for the design of PROTAC linkers: a critical review. Explor. Target. Antitumor Ther. 1(5), 273–312 (2020).
  MedlineGoogle Scholar
• 37. Li X, Song Y. Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy. J. Hematol. Oncol. 13(1), 50 (2020).
  MedlineGoogle Scholar
• 38. Li X, Yao Y, Wu F, Song Y. A proteolysis-targeting chimera molecule selectively degrades ENL and inhibits malignant gene expression and tumor growth. J. Hematol. Oncol. 15, 41 (2022).
  Medline CASGoogle Scholar
• 39. Shulman M, Shi R, Zhang Q. Von Hippel-Lindau tumor suppressor pathways & corresponding therapeutics in kidney cancer. J. Genet. Genomics 48(7), 552–559 (2021).
  Medline CASGoogle Scholar
• 40. Bharathkumar N, Sunil A, Meera P et al. CRISPR/Cas-based modifications for therapeutic applications: a review. Mol. Biotechnol. 64(4), 355–372 (2022).
  Medline CASGoogle Scholar
• 41. Sun X, Gao H, Yang Y et al. PROTACs: great opportunities for academia and industry. Signal Transduct. Target. Ther. 4(1), 64 (2019). •• Recent research revealed that more target binders and more E3 ligases applicable for developing proteolysis-targeting chimeras are waiting for exploration.
  MedlineGoogle Scholar
• 42. Lee H, Puppala D, Choi E-Y, Swanson H, Kim K-B. Targeted degradation of the aryl hydrocarbon receptor by the PROTAC approach: a useful chemical genetic tool. ChemBioChem 8(17), 2058–2062 (2007).
  Medline CASGoogle Scholar
• 43. Powell CE, Gao Y, Tan L et al. Chemically induced degradation of anaplastic lymphoma kinase (ALK). J. Med. Chem. 61(9), 4249–4255 (2018).
  Medline CASGoogle Scholar
• 44. Salami J, Alabi S, Willard RR et al. Androgen receptor degradation by the proteolysis-targeting chimera ARCC-4 outperforms enzalutamide in cellular models of prostate cancer drug resistance. Commun. Biol. 1(1), 100 (2018).
  MedlineGoogle Scholar
• 45. Wang Z, He N, Guo Z et al. Proteolysis targeting chimeras for the selective degradation of Mcl-1/Bcl-2 derived from nonselective target binding ligands. J. Med. Chem. 62(17), 8152–8163 (2019).
  Medline CASGoogle Scholar
• 46. McCoull W, Cheung T, Anderson E et al. Development of a novel B-cell lymphoma 6 (BCL6) PROTAC to provide insight into small molecule targeting of BCL6. ACS Chem. Biol. 13(11), 3131–3141 (2018).
  Medline CASGoogle Scholar
• 47. Lai AC, Toure M, Hellerschmied D et al. Modular PROTAC design for the degradation of oncogenic BCR-ABL. Angew. Chemie Int. Ed. 55(2), 807–810 (2016). •• The synthesis of proteolysis-targeting chimera compounds that mediate the degradation of c-ABL and BCR-ABL by recruiting either cereblon or Von Hippel–Lindau E3 ligases is reported.
  Medline CASGoogle Scholar
• 48. Bai L, Zhou B, Yang C-Y et al. Targeted degradation of BET proteins in triple-negative breast cancer. Cancer Res. 77(9), 2476–2487 (2017).
  Medline CASGoogle Scholar
• 49. Zoppi V, Hughes SJ, Maniaci C et al. Iterative design and optimization of initially inactive proteolysis targeting chimeras (PROTACs) identify VZ185 as a potent, fast, and selective von Hippel–Lindau (VHL) based dual degrader probe of BRD9 and BRD7. J. Med. Chem. 62(2), 699–726 (2019).
  Medline CASGoogle Scholar
• 50. Buhimschi AD, Armstrong HA, Toure M et al. Targeting the C481S ibrutinib-resistance mutation in Bruton’s tyrosine kinase using PROTAC-mediated degradation. Biochemistry 57(26), 3564–3575 (2018).
  Medline CASGoogle Scholar
• 51. Chu T-T, Gao N, Li Q-Q et al. Specific knockdown of endogenous Tau protein by peptide-directed ubiquitin-proteasome degradation. Cell Chem. Biol. 23(4), 453–461 (2016).
  Medline CASGoogle Scholar
• 52. Lu M, Liu T, Jiao Q et al. Discovery of a Keap1-dependent peptide PROTAC to knockdown Tau by ubiquitination–proteasome degradation pathway. Eur. J. Med. Chem. 146, 251–259 (2018).
  Medline CASGoogle Scholar
• 53. Silva MC, Ferguson FM, Cai Q et al. Targeted degradation of aberrant Tau in frontotemporal dementia patient-derived neuronal cell models. Elife 8, e45457 (2019).
  Medline CASGoogle Scholar
• 54. Ramadas B, Kumar Pain P, Manna D. LYTACs: an emerging tool for the degradation of non-cytosolic proteins. ChemMedChem 16(19), 2951–2953 (2021).
  Medline CASGoogle Scholar
• 55. Zhong Y, Chi F, Wu H et al. Emerging targeted protein degradation tools for innovative drug discovery: from classical PROTACs to the novel and beyond. Eur. J. Med. Chem. 231, DOI:10.1016/j.ejmech.2022.114142 (2022).
  MedlineGoogle Scholar
• 56. Banik SM, Pedram K, Wisnovsky S, Ahn G, Riley NM, Bertozzi CR. Lysosome-targeting chimaeras for degradation of extracellular proteins. Nature 584(7820), 291–297 (2020).
  Medline CASGoogle Scholar
• 57. Yin L, Zhou Y, Liu H, Li Y. LYECs: lysosome-enhancing compounds as potential therapeutic approaches for Alzheimer disease. Autophagy 1–2 DOI:10.1080/15548627.2022.2131247 (2022).
  MedlineGoogle Scholar
• 58. Wu S, Xiao H, Sun Q. New approaches for small molecule-induced protein degradation. Future Med. Chem. 13(5), 439–441 (2021).
  CASGoogle Scholar
• 59. Paudel RR, Lu D, Roy Chowdhury S, Monroy EY, Wang J. Targeted protein degradation via lysosomes. Biochemistry 62(3), 564–579 (2023).
  Medline CASGoogle Scholar
• 60. Mishra J, Bhatti GK, Sehrawat A et al. Modulating autophagy and mitophagy as a promising therapeutic approach in neurodegenerative disorders. Life Sci. 311, DOI:10.1016/j.lfs.2022.121153 (2022).
  MedlineGoogle Scholar
• 61. Xiao M, Zhao J, Wang Q, Liu J, Ma L. Recent advances of degradation technologies based on PROTAC mechanism. Biomolecules 12(9), 1257 (2022).
  Medline CASGoogle Scholar
• 62. Zaffagnini G, Martens S. Mechanisms of selective autophagy. J. Mol. Biol. 428(9 Part A), 1714–1724 (2016).
  Medline CASGoogle Scholar
• 63. Pei J, Wang G, Feng L et al. Targeting lysosomal degradation pathways: new strategies and techniques for drug discovery. J. Med. Chem. 64(7), 3493–3507 (2021).
  Medline CASGoogle Scholar
• 64. Cotton AD, Nguyen DP, Gramespacher JA, Seiple IB, Wells JA. Development of antibody-based PROTACs for the degradation of the cell-surface immune checkpoint protein PD-L1. J. Am. Chem. Soc. 143(2), 593–598 (2021).
  Medline CASGoogle Scholar
• 65. Ruffilli C, Roth S, Rodrigo M, Boyd H, Zelcer N, Moreau K. Proteolysis targeting chimeras (PROTACs): a perspective on integral membrane protein degradation. ACS Pharmacol. Transl. Sci. 5(10), 849–858 (2022).
  Medline CASGoogle Scholar
• 66. Ghosh S, Ramadas B, Manna D. Targeted protein degradation using the lysosomal pathway. RSC Med. Chem. 13(12), 1476–1494 (2022).
  Medline CASGoogle Scholar
• 67. Ahn G, Banik SM, Bertozzi CR. Degradation from the outside in: Targeting extracellular and membrane proteins for degradation through the endolysosomal pathway. Cell Chem Biol. 28, 1072–1080 (2021).
  Medline CASGoogle Scholar
• 68. Siepe DH, Picton LK, Garcia KC. Receptor elimination by E3 ubiquitin ligase recruitment (REULR): a targeted protein degradation toolbox. bioRxiv doi: 10.1101/2022.10.31.514624 (2022).
  Google Scholar
• 69. Krah S, Sellmann C, Rhiel L et al. Engineering bispecific antibodies with defined chain pairing. N. Biotechnol. 39, 167–173 (2017).
  Medline CASGoogle Scholar
• 70. Zhang H, Han Y, Yang Y et al. Covalently engineered nanobody chimeras for targeted membrane protein degradation. J. Am. Chem. Soc. 143(40), 16377–16382 (2021).
  Medline CASGoogle Scholar
• 71. Han Y, Yang Z, Hu H et al. Covalently engineered protein minibinders with enhanced neutralization efficacy against escaping SARS-CoV-2 variants. J. Am. Chem. Soc. 144(13), 5702–5707 (2022).
  Medline CASGoogle Scholar
• 72. Luo F, Luo M, Rong Q-X et al. Niclosamide, an antihelmintic drug, enhances efficacy of PD-1/PD-L1 immune checkpoint blockade in non-small cell lung cancer. J. Immunother. Cancer 7(1), 245 (2019).
  MedlineGoogle Scholar
• 73. VanDyke D, Taylor JD, Kaeo KJ, Hunt J, Spangler JB. Biologics-based degraders – an expanding toolkit for targeted-protein degradation. Curr. Opin. Biotechnol. 78, DOI: 10.1016/j.copbio.2022.102807 (2022).
  MedlineGoogle Scholar
• 74. Takahashi D, Arimoto H. Selective autophagy as the basis of autophagy-based degraders. Cell Chem. Biol. 28(7), 1061–1071 (2021).
  Medline CASGoogle Scholar
• 75. Nozawa T, Sano S, Minowa-Nozawa A et al. TBC1D9 regulates TBK1 activation through Ca²⁺ signaling in selective autophagy. Nat. Commun. 11(1), 770 (2020).
  Medline CASGoogle Scholar
• 76. Sorbara MT, Girardin SE. Emerging themes in bacterial autophagy. Curr. Opin. Microbiol. 23, 163–170 (2015).
  Medline CASGoogle Scholar
• 77. Takahashi D, Moriyama J, Nakamura T et al. AUTACs: cargo-specific degraders using selective autophagy. Mol. Cell 76(5), 797–810.e10 (2019).
  Medline CASGoogle Scholar
• 78. Takahashi D, Arimoto H. Targeting selective autophagy by AUTAC degraders. Autophagy 16(4), 765–766 (2020).
  Medline CASGoogle Scholar
• 79. Li Z, Zhu C, Ding Y, Fei Y, Lu B. ATTEC: a potential new approach to target proteinopathies. Autophagy 16(1), 185–187 (2020).
  Medline CASGoogle Scholar
• 80. Narendra DP, Youle RJ. Targeting mitochondrial dysfunction: role for PINK1 and Parkin in mitochondrial quality control. Antioxid. Redox Signal. 14, 1929–1938(2011).
  Medline CASGoogle Scholar
• 81. Li Z, Wang C, Wang Z et al. Allele-selective lowering of mutant HTT protein by HTT–LC3 linker compounds. Nature 575(7781), 203–209 (2019).
  Medline CASGoogle Scholar
• 82. Kanner SA, Shuja Z, Choudhury P, Jain A, Colecraft HM. Targeted deubiquitination rescues distinct trafficking-deficient ion channelopathies. Nat. Methods 17(12), 1245–1253 (2020).
  Medline CASGoogle Scholar
• 83. Siriwardena SU, Munkanatta Godage DNP, Shoba VM et al. Phosphorylation-inducing chimeric small molecules. J. Am. Chem. Soc. 142(33), 14052–14057 (2020).
  Medline CASGoogle Scholar
• 84. Ji CH, Kim HY, Lee MJ et al. The AUTOTAC chemical biology platform for targeted protein degradation via the autophagy-lysosome system. Nat. Commun. 13(1), 904 (2022).
  Medline CASGoogle Scholar
• 85. Garber K. The lysosomal degraders. Nat. Biotechnol. 40, 1709–1713 (2022).
  Medline CASGoogle Scholar
• 86. Ding Y, Xing D, Fei Y, Lu B. Emerging degrader technologies engaging lysosomal pathways. Chem. Soc. Rev. 51(21), 8832–8876 (2022).
  Medline CASGoogle Scholar
• 87. Mieland AO, Beyer M, Krämer OH. News and views. Arch. Toxicol. 96(7), 2143–2144 (2022).
  Medline CASGoogle Scholar
• 88. Dong G, Ding Y, He S, Sheng C. Molecular glues for targeted protein degradation: from serendipity to rational discovery. J. Med. Chem. 64(15), 10606–10620 (2021).
  Medline CASGoogle Scholar
• 89. Luh LM, Scheib U, Juenemann K, Wortmann L, Brands M, Cromm PM. Prey for the proteasome: targeted protein degradation – a medicinal chemist’s perspective. Angew. Chemie Int. Ed. 59(36), 15448–15466 (2020). • Comprehensive overview of chemical biology techniques inducing TPD; explains the strengths and weaknesses of these methods.
  Medline CASGoogle Scholar
• 90. Hua L, Zhang Q, Zhu X, Wang R, You Q, Wang L. Beyond proteolysis-targeting chimeric molecules: designing heterobifunctional molecules based on functional effectors. J. Med. Chem. 65(12), 8091–8112 (2022).
  Medline CASGoogle Scholar
• 91. Alabi SB, Crews CM. Major advances in targeted protein degradation: PROTACs, LYTACs, and MADTACs. J. Biol. Chem. 296, DOI: 10.1016/j.jbc.2021.100647 (2021).
  MedlineGoogle Scholar
• 92. Orensteina SJ, Cuervo AM. Chaperone-mediated autophagy: Molecular mechanisms and physiological relevance. Semin. Cell Dev. Biol. 21, 719–726 (2010).
  MedlineGoogle Scholar
• 93. Zhao L, Zhao J, Zhong K, Tong A, Jia D. Targeted protein degradation: mechanisms, strategies and application. Signal Transduct. Target. Ther. 7(1), 113 (2022).
  Medline CASGoogle Scholar
• 94. Miao Y, Gao Q, Mao M et al. Bispecific aptamer chimeras enable targeted protein degradation on cell membranes. Angew. Chemie Int. Ed. 60(20), 11267–11271 (2021).
  Medline CASGoogle Scholar
• 95. Yan AC, Levy M. Aptamers and aptamer targeted delivery. RNA Biol. 6, 316–320 (2009).
  Medline CASGoogle Scholar
• 96. Fan R, Xiao C, Wan X et al. Small molecules with big roles in microRNA chemical biology and microRNA-targeted therapeutics. RNA Biol. 16, 707–718 (2019).
  MedlineGoogle Scholar
• 97. Xie H, Liu J, Glison DM, Fleming JB. The clinical advances of proteolysis targeting chimeras in oncology. Explor. Target Antitumor Ther. 2, 511–521 (2021).
  Medline CASGoogle Scholar